WEBVTT

00:00:02.200 --> 00:00:04.857
Sexual desire begins with signals in the brain.

00:00:04.901 --> 00:00:10.113
PT-141, also called bremelanotide, grew from
research into a family

00:00:10.113 --> 00:00:12.256
of messengers called melanocortins.

00:00:12.407 --> 00:00:16.735
By 2002, Palatin Technologies in Cranbury, New
Jersey, was reporting

00:00:16.735 --> 00:00:17.725
human trials.

00:00:17.904 --> 00:00:22.062
A 2003 paper by Peter Molinoff, Annette
Shadiack and colleagues

00:00:22.062 --> 00:00:23.376
described its development.

00:00:23.518 --> 00:00:27.565
That gives PT-141 more than two decades of
clinical research

00:00:27.565 --> 00:00:28.089
history.

00:00:28.162 --> 00:00:32.924
Bremelanotide is a ring-shaped peptide
containing seven amino acids.

00:00:33.080 --> 00:00:37.227
It activates several melanocortin receptors,
including receptors found in the

00:00:37.227 --> 00:00:37.712
brain.

00:00:37.902 --> 00:00:42.601
Its precise mechanism for improving low sexual
desire remains unknown.

00:00:42.789 --> 00:00:46.576
Early studies investigated sexual responses in
men.

00:00:46.684 --> 00:00:51.099
Later development focused on women experiencing
persistently low desire that

00:00:51.099 --> 00:00:52.128
caused distress.

00:00:52.300 --> 00:00:58.464
Two phase three RECONNECT trials randomized
1,267 premenopausal women to

00:00:58.464 --> 00:01:01.651
bremelanotide or placebo for twenty-four weeks.

00:01:01.839 --> 00:01:06.857
Women receiving bremelanotide reported greater
improvements in desire and reductions

00:01:06.857 --> 00:01:08.047
in related distress.

00:01:08.188 --> 00:01:11.281
The trials did not show a significant advantage
in the

00:01:11.281 --> 00:01:13.710
number of satisfying sexual events.

00:01:13.884 --> 00:01:19.593
In June 2019, the FDA approved Vyleesi for
acquired, generalized

00:01:19.593 --> 00:01:23.394
hypoactive sexual desire disorder in
premenopausal women.

00:01:23.526 --> 00:01:27.742
By 2026, that represents seven years since U.S.

00:01:27.742 --> 00:01:28.332
approval.

00:01:28.482 --> 00:01:32.252
This is a specific indication, not a general
sexual-performance claim.

00:01:32.402 --> 00:01:36.075
Nausea, flushing and headache are important
side effects.

00:01:36.239 --> 00:01:40.589
Blood pressure can temporarily rise, and the
medicine is contraindicated

00:01:40.770 --> 00:01:44.445
in uncontrolled hypertension or known
cardiovascular disease.

00:01:44.580 --> 00:01:49.815
PT-141 connects decades of peptide research
with a distinct approach

00:01:49.815 --> 00:01:53.985
to sexual health: studying desire, its
biological signals, and the

00:01:53.985 --> 00:01:56.203
distress that can accompany its loss.

00:01:56.375 --> 00:01:58.204
World Peptide Foundation.

00:01:58.369 --> 00:01:59.865
Peptides in 2.

00:02:00.015 --> 00:02:01.663
Every experience matters.